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The soluble receptor of advanced glycation end product
(sRAGE) prevents vascular damage in experimental animal
models, and observational studies in the general population
support the hypothesis that sRAGE may exert a protective
role on the vasculature. To test this in patients with chronic
kidney disease, we determined the relationship between
plasma sRAGE and carotid atherosclerosis in 142 patients
with an average estimated glomerular filtration rate (eGFR) of
32ml/min per 1.73m2 and 49 healthy control individuals
matched for age and gender. Plasma sRAGE was significantly
higher in patients with chronic kidney disease than in the
control cohort. In an aggregate analysis of the patients and
controls, there was a significant inverse relationship between
eGFR and sRAGE, with a breakpoint in the regression line at
64ml/min per 1.73m2. Significant inverse relationships were
found for sRAGE to intima–media thickness and plaque
number in the patients with chronic kidney disease, but no
such associations were found in the controls. On covariance
analysis, the slopes of intima–media thickness and plaque
number to sRAGE were significantly steeper in patients with
chronic kidney disease than in the controls. Furthermore, a
significant interaction was found between sRAGE and
smoking for predicting atherosclerotic plaques in patients
with chronic kidney disease. The pathophysiological
significance of this correlation will have to await more
mechanistic studies.
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Advanced glycation end products (AGEs) are proteins or
lipids that become glycated after exposure to sugars. These
compounds are present in the diabetic vasculature in which
they have a relevant role in atherosclerosis.1 AGEs contribute
to a variety of microvascular and macrovascular complica-
tions through the formation of cross-links between molecules
in the basement membrane of the extracellular matrix and by
engaging the receptor for advanced glycation end products
(RAGE).2 In part due to the decline in renal clearance,3,4
circulating plasma AGEs accumulate in renal insufficiency.
AGEs have indeed been shown to increase up to 18-fold in
peritoneal dialysis patients, and up to 40-fold in those on
hemodialysis.3
Besides AGEs, RAGE has the ability to bind several other
pro-inflammatory molecules.5–7 Given the high number of
pro-inflammatory ligands, it has become increasingly evident
that the pathophysiological role of this receptor can actually
extend widely beyond diabetes. RAGE exists in several
variants, that is, as a transmembrane receptor on the cell
surface or as isoform lacking the N-terminal domain
(N-truncated variant) or the C-terminal (transmembrane)
domain (C-truncated variant). The C-truncated RAGE
variant, a 50-kd protein, is mainly produced in endothelial
cells by means of regulated alternative splicing or carbox-
yterminal truncation through metalloproteinases.8,9 This
receptor is known as soluble RAGE (sRAGE) or endogenous
secretory RAGE, a naturally occurring inhibitor of the
AGE–RAGE interaction. In animal models, the administra-
tion of sRAGE reduces the severity of atherosclerosis to the
same level as that found in euglycemic control mice.10
Blockade of RAGE by sRAGE in mice with diabetes reduces
atherosclerotic lesion area, supporting the notion that RAGE
is a crucial part of the development and acceleration of
atherosclerosis in diabetes, and that sRAGE is an effective
intervention.11,12
Clinical studies in nondiabetic subjects have shown that
higher levels of endogenous sRAGE may be associated with a
lower incidence of coronary artery disease13 and hypertension.14
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Recently, higher sRAGE levels have been found in
patients with decreased renal function, mainly in patients
with end-stage renal disease (ESRD),15 but the implications
of high levels of sRAGE for atherosclerosis in patients
with chronic kidney disease (CKD) are still unclear. With
this background in mind and considering the high cardio-
vascular (CV) risk portended by CKD, we analyzed
the relationship between plasma sRAGE and atherosclerosis
in patients with moderate-to-severe CKD and in a series of
healthy subjects who were well matched for age and sex.
RESULTS
The prevalence of diabetes mellitus in CKD patients was 25%
(that is, 36 patients out of 142). In all, 75 patients were
habitual smokers and 129 patients (91%) were on anti-
hypertensive treatment, and 13 patients (9%) had had major
CV events (myocardial infarction and stroke) before the start
of the study. As shown in Table 1, CKD patients and healthy
subjects were accurately matched for age and gender.
However, CKD patients had higher systolic blood pressure,
triglycerides, glucose, and calcium phosphate product, and
lower hemoglobin and cholesterol when compared with
control subjects (Table 1). The internal diameter of carotid
arteries and total number of plaques were both significantly
higher in CKD patients than in controls, whereas intima–-
media thickness (IMT) was only moderately increased
(P¼NS; Table 1).
Effect of age on plasma sRAGE in CKD patients and in
controls
Plasma sRAGE was higher (Po0.001) in CKD patients than
in healthy subjects (Table 1), and the circulating levels of this
receptor correlated in an inverse manner with age in CKD
patients (r¼0.45, Po0.001) but not in healthy control
subjects. Accordingly, in CKD patients, a 1-year increase in
age was associated with a 39-pg/ml decrease in plasma
sRAGE, a figure significantly higher (covariance analysis,
P¼ 0.003) than that in controls (5.9 pg/ml increase in sRAGE
for a 1-year increase in age).
Renal function and plasma sRAGE: a breakpoint analysis in
patients and controls (n¼ 191)
In an aggregate analysis of CKD patients and controls
(n¼ 191), there was a linear, inverse relationship between
estimated glomerular filtration rate (eGFR) and plasma
sRAGE (r¼0.38, Po0.001). The breakpoint analysis
identified 64ml/min per 1.73m2 as a significant breakpoint
of the regression line between plasma sRAGE and eGFR
(Figure 1). A breakpoint analysis that was carried out in the
subgroup of CKD patients and healthy subjects in which 24 h
creatinine clearance was available (n¼ 115) identified a
creatinine clearance value of 63ml/min as a significant
breakpoint of the creatinine clearance–sRAGE regression line,
a figure almost identical to that obtained by using the
Modification of Diet in Renal Diseases formula (64ml/min).
Plasma sRAGE and carotid atherosclerosis: analysis of
covariance
In CKD patients, plasma sRAGE was strongly and inversely
related with IMT (r¼0.31, Po0.001; Figure 2) and with
Table 1 |Main demographic, somatometric, clinical, and
biochemical data in CKD patients and in controls
CKD patients
(n=142)
Controls
(n=49) P-value
Age (years) 56±13 55±11 0.57
BMI (kg/m2) 27.8±4.6 27.4±3.8 0.58
Male sex (n, %) 80 (56) 28 (57) 1.00
Smokers (n, %) 75 (53) 21 (43) 0.18
Diabetic patients (n, %) 36 (25) 0 o0.001
Previous myocardial
infarction/stroke (n, %)
13 (9) 0 o0.001
On anti-hypertensive
treatment (n, %)
129 (91) 0 o0.001
Systolic blood pressure
(mmHg)
132±20 123±10 o0.001
Diastolic blood pressure
(mmHg)
79±12 78±8 0.87
Heart rate (beats/min) 72±10 73±10 0.38
Hemoglobin (g/dl) 12.6±1.8 13.6±1.6 o0.001
Total cholesterol (mg/dl) 171±39 186±33 0.01
Triglycerides (mg/dl) 150±77 100±46 o0.001
Albumin (g/dl) 4.0±0.6 3.9±0.5 0.27
Glucose (mg/dl) 110±44 98±12 0.008
Calcium (mmol/l) 2.27±0.17 2.21±0.48 0.33
Phosphate (mmol/l) 1.94±0.37 1.59±0.27 o0.001
Creatinine (mg/dl) 2.5±1.4 0.87±0.17 o0.001
GFR (ml/min per 1.73m2) 32±15 89±17 o0.001
CRP (mg/l) 1.67 (0.73–5.18) 1.50 (0.65–3.30) 0.31
Intima–media thickness (mm) 0.68±0.14 0.66±0.15 0.46
Internal diameter of carotid
arteries (mm)
6.6±0.8 5.9±0.7 o0.001
Total number of plaques (n) 2.1 (0.0–11.0) 0.5 (0.0–7.0) o0.001
sRAGE (pg/ml) 1780 (1152–2662) 1072 (460–1816) o0.001
Abbreviations: BMI, body mass index; CKD, chronic kidney disease; CRP, C-reactive
protein; GFR, glomerular filtration rate; sRAGE, soluble receptor of advanced
glycation end product. Data are expressed as mean±s.d., median, and inter-quartile
or as percentage frequency, as appropriate.
Significant differences are shown in bold.
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Figure 1 | Segmented linear regression analysis (breakpoint
analysis) of plasma soluble receptor of advanced glycation
end product (sRAGE) and estimated glomerular filtration rate
(eGFR) in chronic kidney disease (CKD) patients (K) and in
healthy subjects (J). The best breakpoint of eGFR (64ml/min
per 1.73m2) is indicated by the arrow.
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the total number of atherosclerotic plaques (r¼0.24,
P¼ 0.005), but unrelated with the internal diameter of the
carotid artery (r¼0.15, P¼ 0.08). The exclusion of diabetic
patients (n¼ 36) did not materially affect the strength of
these relationships (sRAGE–IMT link: r¼0.32, P¼ 0.001;
sRAGE–plaque number link: r¼0.23, P¼ 0.02). In healthy
subjects, IMT (r¼ 0.09, P¼ 0.53), plaques number (r¼ 0.07,
P¼ 0.65), and the internal diameter of the carotid arteries
(r¼ 0.16, P¼ 0.28) were unrelated to sRAGE. Notably, on
covariance analysis the slopes of IMT and plaque number
relationships with plasma sRAGE were significantly steeper in
CKD patients (estimated decrease in IMT for each unitary
increase in log sRAGE: 0.16mm vs 0.03mm, P¼ 0.001;
estimated decrease in plaque numbers for each unitary
increase in log sRAGE: 2.2 plaques vs 0.2 plaques, P¼ 0.01)
than the corresponding relationships in healthy subjects.
Remarkably, such differences were little affected by data
adjustment for smoking, systolic pressure, hemoglobin,
cholesterol, triglycerides, calcium phosphate product, glu-
cose, and eGFR (estimated increase in IMT for each unitary
increase in log sRAGE: 0.14mm vs 0.01mm, P¼ 0.008;
estimated increase in plaque numbers for each unitary
increase in log sRAGE: 1.9 plaques vs 0.1 plaques, P¼ 0.04).
In the whole group of CKD patients and controls, no
interaction was found between sRAGE with smoking,
diabetes, cholesterol, triglycerides, and systolic pressure for
predicting both IMT and total number of atherosclerotic
plaques.
Plasma sRAGE and atherosclerotic plaques in CKD patients
In a logistic regression model testing (backward strategy) of
all variables that are listed in Table 1 and the plausible
interactions between sRAGE and other risk factors (smoking,
diabetes, cholesterol, and hypertension), only age (odds ratio
(OR, 1 year) 1.12, 95% confidence interval (CI) 1.07–1.17,
Po0.001), male sex (OR 4.05, 95% CI 1.36–12.1, P¼ 0.01),
phosphate (OR (1mmol/l) 3.42, 95% CI 0.90–13.0, P¼ 0.07),
and the sRAGE–smoking interaction (45 cigarettes/day;
P¼ 0.016) maintained an independent relationship with the
presence of atherosclerotic plaques. These variables jointly
produced a receiver operating characteristic curve area of
0.88, 95% CI 0.82–0.94. A logistic regression model excluding
this interaction term produced a modest (2%) decrease in
the receiver operating characteristic curve area (0.86 (95% CI:
0.79–0.92). Akaike weights analyses showed that the model
including sRAGE smoking interaction term had 70%
chances to be the best model for predicting atherosclerotic
plaques in CKD patients.
Western blot analysis
A western blot analysis on 10 sera from control subjects
(n¼ 5) and CKD patients (n¼ 5) revealed two bands,
corresponding to sRAGE isoforms of 50 and 55 kDa
(Figure 3). It is noteworthy that there is no trace of sRAGE
fragmentation, either in control subjects or in CKD patients.
DISCUSSION
This survey in patients with CKD shows that circulating
sRAGE levels are inversely related with GFR only when the
eGFR is below a threshold level of approximately 60ml/min
per 1.73m2 and that this soluble receptor is associated in an
inverse manner with atherosclerosis in these patients. Overall,
the data are compatible with the hypothesis that high sRAGE
may act as a vasculoprotective factor in this population.
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Figure 2 |Relationship between plasma soluble receptor of advanced glycation end product (sRAGE) with intima–media thickness (IMT)
and total number of plaques in chronic kidney disease patients and in healthy subjects. Data are correlation coefficients and P-values.
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Atherosclerosis is a major cause of death and CV
complications in patients with CKD, and several studies
have documented that the risk for such complications starts
to rise when the GFR falls below 60ml/min.16 In analyses
adjusting for the full series of Framingham risk factors and
background CV events, the incidence of CV death in patients
with moderate CKD is indeed 40–100% higher than that of
the coeval general population.17 Various factors contribute to
vascular damage in CKD,18 including Framingham factors
(that is, hypertension, smoking, diabetes, and dyslipidemia),
disease-specific factors (that is, anemia and hyperpho-
sphatemia-hyperparathyroidism), and emerging factors, such
as elevated C-reactive protein, and accumulation of the
endogenous inhibitor of endothelial nitric oxide synthase,
asymmetric dimethylarginine, but in the aggregate, classic
and emerging risk factors fail to explain in full the excess risk
for atherosclerosis in these patients.19,20
Advanced glycation end products are generated as a result
of chronic hyperglycemia and enhanced oxidative stress.
These modified proteins interact with receptors, such as
RAGE, thereby inducing oxidative stress, inflammation, and
extracellular matrix accumulation, all effects that eventually
translate into accelerated plaque formation and increased
cardiac fibrosis in diabetic patients.2 The potential implica-
tion of AGEs for human atherosclerosis is indicated by the
observation that strategies that limit AGEs binding to their
receptors, such as agents that reduce tissue AGEs accumula-
tion, attenuate atherosclerosis in experimental models.11,12
In addition to the endogenous synthesis, AGEs are
generated during roasting, broiling, and frying of foods,
and are absorbed in the gastrointestinal tract.21 The amount
of AGEs ingested with a conventional diet is considerably
higher than the total amount of AGEs in tissues. Beyond
diabetes, AGEs are elevated in patients with CKD, a
phenomenon depending on the fact that dietary AGEs are
inadequately removed by the failing kidney.3,22
High AGE levels in patients with ESRD have been
associated with concentric left ventricular hypertrophy,23 a
geometric pattern that comes along with arterial stiffness24,25
and that is a strong risk factor for mortality in this
population. However, other studies in patients with moder-
ate-to-severe CKD did not confirm an independent associa-
tion between AGEs and left ventricular hypertrophy or
carotid atherosclerosis,26 whereas a paradoxical association
between a major AGE (N-epsilon-carboxymethyllysine ad-
ducts) and mortality was reported in patients with ESRD
patients.27 These discrepant results indicate that the inter-
pretation of the link between AGEs and clinical outcomes is
complex because the risk factors associated with the plasma
concentration of these compounds, such as inflammation
and malnutrition,28,29 may confound the link between AGEs,
atherosclerosis, and clinical outcomes.
Soluble RAGE is shed from cell-surface RAGE and
effectively binds circulating AGEs, thus antagonizing down-
stream RAGE signaling at the tissue level.30 Independent of
other risk factors, sRAGE is significantly lower in patients
with angiographically proven coronary artery disease than in
age-matched healthy controls,13 and this was also recently
proven to be the case in a large population with diabetes.
Carotid IMT was reported to be inversely associated with
sRAGE in studies in diabetic31 and in non-diabetic32 patients.
In the largest survey on sRAGE performed so far in a
combined series of diabetic and non-diabetic subjects,
circulating levels of this soluble receptor were inversely
related with IMT.32 However, such an association was much
stronger in non-diabetic subjects than in diabetic patients,
highlighting the potential importance of sRAGE in disease
states other than diabetes.33
Renal function is an important determinant of sRAGE in
diabetic and non-diabetic patients with CKD.15,32,34 sRAGE
attain very high levels when renal function is virtually
abolished, such as in ESRD patients, to substantially decrease
when it is restored by renal transplantation.35,36 A potential
protective role of sRAGE in patients with ESRD is suggested
by the observation that relatively lower levels of this
circulating receptor is a risk marker for incident CV
complications in this population.37 However, this latter study
had insufficient power to establish whether such an
association was independent of other risk factors.
Our study is the first to analyze the relationship between
carotid atherosclerosis and sRAGE in CKD patients with
various degrees of renal function. The issue is relevant
because in this particular population reduced renal function
is an important confounder for the interpretation of the link
between this soluble receptor and atherosclerosis. In this
regard, our analysis identifies a GFR of approximately 60ml/
min as a threshold below which sRAGE accumulates.
Although there is still some controversy on the GFR level
below which excessive CV risk starts to rise in CKD, this
threshold is also the level below which the risk for CV and
other complications starts to rise in CKD, and coincides with
the limit of GFR used to define stage 3 CKD according to
current international guidelines.16 While specifically con-
firming in CKD patients the previous findings in non-
diabetic and diabetic patients, in this study we show for the
first time that reduced renal function and low sRAGE concur
in determining the severity of atherosclerosis in this
particular population. Although we still ignore the precise
mechanism whereby sRAGE increases in CKD, it may well be
c1 c2 c3 c4 c5 P1 P2 P3 P4 P5
50 kDa
Figure 3 |Western blot of serum soluble receptor of advanced
glycation end product (sRAGE) on control subjects and
patients with chronic kidney disease (CKD). Serum samples
from five control subjects (C1–C5) and five patients with CKD
(P1–P5) were electrophoresed, blotted, and probed with anti-
RAGE antibody as described in the Methods section. Two bands
corresponding to sRAGE isoforms (50 and 55 kDa) are present in
both control subjects and patients.
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a counter-regulatory mechanism activated to counter the
vasculotoxic effect of AGEs accumulation. Furthermore,
interaction analysis revealed that the plasma levels of sRAGE
interact with moderate-to-severe smoking (45 cigarettes/
day) in CKD patients for predicting carotid plaques and that
this interaction term adds significant but modest predictive
value to other risk factors for the identification of CKD
patients with atherosclerotic plaques. It seems unlikely that
the measurement of sRAGE is useful in clinical practice to
identify patients at a higher risk for atheroclerosis. However,
the issue remains to be tested in a specifically designed
clinical trial.
The lack of association between sRAGE and carotid
atherosclerosis in the control group in our study deserves a
comment because it is not in keeping with findings in the
general population in the study by Koyama et al.,37 in which
the correlation between sRAGE and carotid IMT was
substantially stronger than in diabetic subjects. We believe
that the lack of association in our control group depends on
this group being a selected series of healthy individuals with a
low level of atherosclerosis. In community studies, similar to
the study by Koyama et al.,37 the level of atherosclerosis is
higher than in selected series of healthy individuals, which
justifies this apparent discrepancy.
In conclusion, this survey in CKD patients shows
circulating sRAGE levels are associated in an inverse manner
to carotid atherosclerosis. These findings are compatible with
the hypothesis that high sRAGE may act as a vasculoprotec-
tive factor in this population. Longitudinal observations and
intervention studies are warranted to establish whether this
link is causal in nature.
METHODS
This study protocol was in conformity with the ethical
guidelines of our institution, and informed consent was
obtained from each participant.
Patients
We studied 142 patients with CKD. Their mean age was
56±13 years (80 M and 62 F) and their GFR (, Modification
of Diet in Renal Diseases formula38) ranged from 5 to 83ml/
min per 1.73m2, GFR (mean±s.d.) 32±15ml/min per
1.73m2). Out of 142 patients, 36 were diabetic (type I
diabetes 64% and type II diabetes 36%). The main
demographic, somatometric, clinical, and biochemical char-
acteristics of patients included in the study are detailed in
Table 1.
Control group
As control group we selected 49 healthy individuals who were
accurately matched with CKD patients for age (CKD
patients: 56±13 years vs controls: 55±11 years) and sex
(CKD patients, males: 56% vs controls, males: 57%). To be
selected, healthy subjects had to have no alteration at an
extensive clinical and biochemical work-up (including
absence of albuminuria), and had to have normal urine
analysis and eGFR (Modification of Diet in Renal Diseases
study equation formula, see below) X60ml/min per
1.73m2,16 which is the recommended threshold for the
diagnosis of CKD.
Laboratory measurements
Blood sampling was performed after 20–30min of quiet
resting in a semi-recumbent position. After an overnight
fasting, blood samples for serum lipids, creatinine, albumin,
calcium and phosphate, and hemoglobin were obtained from
all patients. GFR was estimated (eGFR) by using the
Modification of Diet in Renal Diseases study equation
formula, equation 7, derived by Levey et al.38 In 82 CKD
patients and in 33 healthy subjects, a 24-h urine collection
was also available, thus allowing the calculation of 24-h
creatinine clearance. Plasma samples were stored at 80 1C
until the analysis. Plasma sRAGE levels were determined
using an enzyme-linked immunosorbent assay kit (DuoSet
ELISA Development kit, R&D systems, Minneapolis, MN,
USA) containing the basic components required for the
development of a double-sandwich enzyme-linked immuno-
sorbent assay, as described earlier.39 Intra- and inter-assay
coefficients of variation values were 5.9 and 8.2%, respec-
tively. The lower limit of detection of sRAGE was 21.5 pg/ml.
Serum C-reactive protein was measured by a high-sensitivity
immuno-turbidimetric method (hsCRP-Dade Behring,
Marburg, Germany).
Western blot
To identify different isoforms of sRAGE in serum, a western
blot analysis was performed. After determination of protein
concentration with the bicinchoninic acid protein assay reagent
(Pierce Biotechnology, USA), equal amounts of proteins were
separated using sodium dodecyl sulfate-polyacrylamide gel
electrophoresis, the resolved proteins were transferred to nitro-
cellulose sheets (Amersham Biosciences, Milan, Italy) and, after
saturation of nonspecific binding sites, incubated overnight
with specific monoclonal anti-human RAGE antibody (2mg/ml,
R&D system). Blots were incubated with peroxidase-conjugated
secondary antibody (Pierce, Biotechnology, Rockford, IL, USA)
for 1 h at room temperature. Protein bands were visualized by
the supersignal west pico chemiluminescent substrate (Pierce).
Echo-color Doppler study
Both in patients and controls, ultrasonographic studies on
common carotid arteries were performed bilaterally by a
single observer blinded to the clinical and biochemical data.
All studies were performed with a GE-Vingmed System 5
(Aliso Viejo, CA, USA) using a 10-MHz high-resolution
probe. The IMT was defined as a low-level echo grey band
that does not project into the arterial lumen. IMT was
measured at end-diastole as the distance from the leading
edge of the second echogenic line of the far walls of the distal
segment of the common carotid artery, the carotid bifurca-
tion, and the initial tract of the internal carotid artery on
both sides. Measurements were performed at 0.5, 1, and 2 cm
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below and above the bifurcation (six measurements on
each side), and the average measurement was taken as IMT.
The internal diameter of the common carotid artery was
measured bilaterally 2 cm below the bifurcation at end-
diastole, and the average measurement was taken as diameter
of the common carotid artery. IMT and diameter of the
common carotid artery measurements were always per-
formed in plaque-free arterial segments. The number of
atherosclerotic plaques (either as faint grey echoes (soft
plaques) or bright white echoes (calcified plaque) protruding
into the lumen) that were detected in the bulbar area (from
2 cm below to 2 cm above the bifurcation) of the carotid
arteries was recorded on both sides and summed up.
Statistical analysis
Data are expressed as mean±s.d., median, and inter-quartile
range or as percentage frequency, and comparisons between
groups were made using t-test, Mann–Whitney test, or
chi-square test, as appropriate. The relationship between
two variables was tested using Pearson’s correlation coeffi-
cient. When required, variables showing a positively-skewed
distribution were log-transformed (lg10) before the correla-
tion analysis. Multifactorial hypotheses were tested using
multiple linear regression analysis.
Segmented linear regression analysis (breakpoint analy-
sis)40 was performed to identify the best breakpoint in eGFR
that minimizes the residual sum of squares between plasma
sRAGE and eGFR. The breakpoint analysis was performed
using a standard, free statistical software (SegReg program,
available on the web http://www.waterlog.info/segreg.htm).
Both crude and adjusted analysis of covariance were used to
directly compare the slopes of regression lines between
plasma sRAGE and IMT on one hand, and the total number
of atherosclerotic plaques in CKD patients and in healthy
subjects on the other. Although the control group was
accurately matched with CKD patients for age and sex, the
potential confounding effect on the slope comparisons and
plaque burden of variables that significantly differed between
the two groups (that is, potential confounders that were not
controlled by matching, see Table 1) was analyzed using
multivariate modeling (adjusted analysis of covariance).
Tested covariates included the remaining Framingham risk
factors (smoking, serum glucose, arterial pressure/anti-
hypertensive treatment, and serum lipids), previous myocar-
dial infarction/stroke, body mass index, factors peculiar to
CKD (hemoglobin, albumin, and calcium phosphate pro-
duct), eGFR/serum creatinine, and serum C-reactive protein.
The independent correlates of atherosclerotic plaques in
CKD patients were identified by logistic regression analysis
using backward elimination strategy (Pout: 0.10) all variables
listed in Table 1 and plausible interactions between sRAGE
and other risk factors (smoking, diabetes, cholesterol, and
hypertension). Data are expressed as OR, 95% CI, and
P-value. The analysis of the effect modification of moderate-
to severe-smoking (45 cigarettes/day) on the sRAGE–ather-
osclerotic plaques relationship was analyzed as suggested by
Altman,41 that is, by simultaneously including sRAGE,
smoking, and sRAGE smoking into the same model. The
performance of predictive models for identifying CKD
patients with atherosclerotic plaques was analyzed using
receiver operating characteristic curve analysis and Akaike
weights calculation.42 All calculations were made using a
standard statistical package (SPSS for Windows Version 9.0.1,
11 Mar-1999, Chicago, IL, USA).
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